Is Celularity Inc. (CELU) a Buy, Sell, or Hold?
Celularity Inc.
NASDAQ:CELU
$0.78 USD
$0.03 (3.31%)
- Volume
- 23.38K
- Average Volume
- 157.05K
- Market Capitalization
- $18.76M
- P/E Ratio
- -0.21
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $4.35
- Year Low
- $0.56
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert Joseph Hariri |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CELU |
| CUSIP | 151190204 |
| CIK | 0001752828 |
| Web | https://www.celularity.com |
| Phone | 908 768 2170 |
| Currency | USD |
| Employees | 115 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Cash Ratio | 0.08 |
Sales & Book Value
| Annual Sales | $26.55M |
| Price / Sales | 0.71 |
| Cash Flow | -0.52 |
| Price / Cash Flow | -1.42 |
| Price / Book | -0.52 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -74.00% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.59 |
| Trailing P/E Ratio | -0.21 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $-91.8M |
| Net Margin | -345.44% |
| Pretax Margin | -345.44% |
| Return on Equity | 411.46% |
| Return on Assets | -85.45% |
Financials Score
| AltmanZ Score | -15.99 |
| Piotroski Score | 3.00 |
| Working Capital | -68.44M |
| Total Assets | 107.33M |
| Ebit | -84.96M |
| Market Cap | 17.81M |
| Total Liabilities | 145.39M |
Poll Results
About Celularity Inc. (NASDAQ:CELU) Stock
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme ... and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
2026-06-04 08:00:00
FLORHAM PARK, N.J. and ORLANDO, Fla.
Celularity Releases CEO Letter to Shareholders
2026-06-03 16:15:00
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
2026-06-03 08:00:00
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026.
Celularity Receives Nasdaq Notice Regarding Form 10-Q
2026-05-29 17:15:00
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company's delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission.
2026-05-01 16:30:00
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for long-term growth
NEXGEL Appoints Ian Blackman as Chief Financial Officer
2026-04-27 09:00:00
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer.
2026-04-21 09:00:00
Transaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Forms BioNX Surgical, a division of NEXGEL LANGHORNE, Pa.
Celularity Announces Closing of Transaction with NexGel
2026-04-21 08:30:00
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously announced transaction with NexGel, Inc. (“NexGel”), pursuant to which NexGel acquired certain commercial and other assets related to Celularity's biomaterials product portfolio and received an exclusive license to develop and commercialize specified products. The transaction is intended to monetize Celularity's biomaterials portfolio while enabling it to further concentrate resources on advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform.
Frequently Asked Questions
-
What is the current Celularity Inc. (CELU) stock price?
-
Celularity Inc.(NASDAQ:CELU) stock price is $0.78 in the last trading session. During the trading session, CELU stock reached the peak price of $4.35 while $0.56 was the lowest point it dropped to. The percentage change in CELU stock occurred in the recent session was 3.31% while the dollar amount for the price change in CELU stock was $0.03.
-
CELU's industry and sector of operation?
-
The NASDAQ listed CELU is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CELU?
-
Kyle Harold Fletcher | Chief Legal and Strategy Officer & Corporate Secretary
Steven N. Gordon | Chief Operating and Administrative Officer & Director
Ricardo J. Gonzalez | Chief Commercial Officer
Robert Joseph Hariri | Founder, Chief Executive Officer & Chairman
John Sprague | Acting Chief Financial Officer -
How many employees does CELU have?
-
Number of CELU employees currently stands at 115. CELU operates from 170 Park Avenue, Florham Park, NJ 07932, US.
-
Link for CELU official website?
-
Official Website of CELU is: https://www.celularity.com
-
How do I contact CELU?
-
CELU could be contacted at phone #908 768 2170 and can also be accessed through its website. CELU operates from 170 Park Avenue, Florham Park, NJ 07932, US.
-
How many shares of CELU are traded daily?
-
The average number of CELU shares traded daily for last 3 months was 157.05K.
-
What is the market cap of CELU currently?
-
The market value of CELU currently stands at $18.76M with its latest stock price at $0.78